Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC

NCT05167604 · clinicaltrials.gov ↗

UNKNOWN

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung
Next-Generation Sequencing
Chemotherapy, Adjuvant
Neoplasm, Residual
Circulating Tumor DNA

Interventions

DRUG: Adjuvants, Pharmaceutic

Sponsor

Tang-Du Hospital